Concentric Medical Files for $69 Million IPO

Published: Aug 17, 2007

MOUNTAIN VIEW, Calif., Aug. 17 /PRNewswire/ -- Concentric Medical, Inc. announced today it has filed a registration statement with the U.S. Securities and Exchange Commission, or SEC, relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in this offering will be sold by Concentric Medical.

Concentric Medical is a medical device company that designs, develops and markets products for restoring blood flow in patients who have suffered ischemic strokes.

Merrill Lynch, Pierce, Fenner & Smith Incorporated and Lehman Brothers Inc. will be acting as joint book-running managers and Thomas Weisel Partners LLC is acting as a co-manager of the offering. The number of shares to be offered and the price range have not yet been determined. This offering will be made only by means of a prospectus. When available, preliminary prospectuses relating to this offering may be obtained from Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080 and from Lehman Brothers Inc., c/o Broadridge Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717.

A registration statement relating to these securities has been filed with the SEC, but it has not yet become effective. Copies of Concentric Medical's S-1 Registration Statement can be accessed over the Internet through the SEC's web site at These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction.

Contact: Andrew Gordon, VP Marketing 650-810-1701

Concentric Medical, Inc.

CONTACT: Andrew Gordon, VP Marketing of Concentric Medical, Inc.,+1-650-810-1701,

Back to news